Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5191456
Max Phase: Preclinical
Molecular Formula: C44H52FN7O8S
Molecular Weight: 858.01
Associated Items:
ID: ALA5191456
Max Phase: Preclinical
Molecular Formula: C44H52FN7O8S
Molecular Weight: 858.01
Associated Items:
Canonical SMILES: Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)COCCOCCNC(=O)c2c(C)[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c2C)C(C)(C)C)cc1
Standard InChI: InChI=1S/C44H52FN7O8S/c1-24-34(19-32-31-17-29(45)11-12-33(31)50-40(32)55)49-25(2)37(24)42(57)46-13-14-59-15-16-60-22-36(54)51-39(44(4,5)6)43(58)52-21-30(53)18-35(52)41(56)47-20-27-7-9-28(10-8-27)38-26(3)48-23-61-38/h7-12,17,19,23,30,35,39,49,53H,13-16,18,20-22H2,1-6H3,(H,46,57)(H,47,56)(H,50,55)(H,51,54)/b32-19-/t30-,35+,39-/m1/s1
Standard InChI Key: FMCCDNIHVMLCTK-XHQJFUIVSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 858.01 | Molecular Weight (Monoisotopic): 857.3582 | AlogP: 4.27 | #Rotatable Bonds: 16 |
Polar Surface Area: 204.08 | Molecular Species: NEUTRAL | HBA: 10 | HBD: 6 |
#RO5 Violations: 2 | HBA (Lipinski): 15 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.39 | CX Basic pKa: 2.65 | CX LogP: 2.47 | CX LogD: 2.47 |
Aromatic Rings: 4 | Heavy Atoms: 61 | QED Weighted: 0.07 | Np Likeness Score: -0.81 |
1. Zhai J, Li C, Sun B, Wang S, Cui Y, Gao Q, Sang F.. (2022) Sunitinib-based Proteolysis Targeting Chimeras (PROTACs) reduced the protein levels of FLT-3 and c-KIT in leukemia cell lines., 78 [PMID:36332882] [10.1016/j.bmcl.2022.129041] |
Source(1):